Q-Med Says $3B Medicis-Valeant Deal Violates Licensing Pact
Q-Med AB launched a suit in New York federal court Wednesday seeking to prevent Medicis Pharmaceutical Corp. from transferring marketing rights for Q-Med's skin care products to rival Valeant Pharmaceuticals International...To view the full article, register now.
Already a subscriber? Click here to view full article